Cytek Biosciences, Inc. CTKB Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $31.81M-66.6% | $28.98M-70.6% | $93.28M-42.5% | $75.47M-57.6% | $95.3M-43.5% | ||
| $227.28M+6.8% | $230.4M+10.7% | $228.48M+12.3% | $224.48M+8.8% | $212.89M+0.8% | ||
| $199.36M+7.1% | $194.91M-0.3% | $190.38M-10.4% | $185.53M-20.2% | $186.11M-25.0% | ||
| $379.3M-0.3% | $392M-1.1% | $388.49M-0.4% | $382.83M-0.3% | $380.5M-2.1% | ||
| $20.47M+14.8% | $18.01M+0.3% | $18.05M-2.5% | $18.35M+1.3% | $17.83M-2.3% | ||
| $16.69M+0.1% | $16.7M+0.2% | $16.7M+3.2% | $16.71M+3.2% | $16.68M+3.1% | ||
| $15.7M-19.2% | $16.82M-16.4% | $17.68M-13.7% | $18.6M-13.2% | $19.43M-12.7% | ||
| $449.11M-6.9% | $461.54M-7.6% | $494.92M+0.8% | $493.32M+2.0% | $482.6M-1.9% | ||
| $27.64M+35.8% | $27.14M+52.2% | $26.26M+71.2% | $24.02M+63.8% | $20.36M+39.9% | ||
| $30.03M+91.1% | $28.5M+77.1% | $16.32M+10.3% | $16.63M+18.2% | $15.72M+3.6% | ||
| $80.94M+19.6% | $77.8M+15.0% | $75.21M+19.8% | $73.27M+39.9% | $67.69M+21.8% | ||
| $386K-58.0% | $525K-50.0% | $655K-47.0% | $791K-40.5% | $918K-37.8% | ||
| $121.47M+18.0% | $119.8M+15.5% | $116.35M+10.0% | $115.76M+22.4% | $102.97M+3.5% | ||
| 1B+781,150% | 1B+775,094% | 128K-1.5% | 127K-3.8% | 128K-2.3% | ||
| -$120.6M-159% | -$101.74M-189% | -$57.66M-28.6% | -$52.18M-14.0% | -$46.6M-31.8% | ||
| $327.64M-13.7% | $341.74M-13.6% | $378.57M-1.8% | $377.56M-3.0% | $379.62M-3.3% | ||
| $449.11M-6.9% | $461.54M-7.6% | $494.92M+0.8% | $493.32M+2.0% | $482.6M-1.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cytek Biosciences, Inc.'s total assets?
- Cytek Biosciences, Inc. (CTKB) holds $449.1M in total assets, down 6.9% year over year.
- How much debt does Cytek Biosciences, Inc. have?
- Cytek Biosciences, Inc. carries $16.8M in total debt against $327.6M of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Cytek Biosciences, Inc. have?
- Cytek Biosciences, Inc. holds $31.8M in cash and equivalents.
- Can Cytek Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 4.69 — current assets exceed current liabilities.
- Where does Cytek Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
